Focal Segmental Glomerulosclerosis Market Report 2026

Focal Segmental Glomerulosclerosis Market Overview

• Focal Segmental Glomerulosclerosis market size has reached to $1.57 billion in 2025 • Expected to grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: The Rise In kidney diseases Fuels The Growth Of The Market Due To Increasing Incidence From Diabetes And CKD Mortality Trends • Market Trend: Innovative Dual-Action Therapy Gains FDA Approval For Rare Kidney Disorder • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Focal Segmental Glomerulosclerosis Market?

Focal segmental glomerulosclerosis (FSGS) is a rare kidney disorder marked by scarring (sclerosis) in segments of some glomeruli, the kidney’s filtering units, resulting in proteinuria and progressive kidney damage. It plays a key role in clinical diagnosis and research aimed at understanding proteinuria-related kidney diseases and developing targeted therapies to prevent kidney failure. The main disease types of focal segmental glomerulosclerosis are primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. Primary focal segmental glomerulosclerosis (FSGS) is a kidney disorder characterized by scarring (sclerosis) in scattered regions (focal) of some glomeruli (segmental), leading to proteinuria and progressive loss of kidney function without a known secondary cause. Treatment options include drug therapy, dialysis, kidney transplantation, and others, with drug classes used being immunosuppressants, angiotensin inhibitors, and corticosteroids. These medications are administered via oral and parenteral routes and are managed across various end-user settings, including hospitals, homecare environments, specialty clinics, and others.

What Is The Focal Segmental Glomerulosclerosis Market Growth Forecast?

The focal segmental glomerulosclerosis market size is expected to see strong growth in the next few years. It will grow to $2.24 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to precision nephrology, early disease biomarkers, biologic drug development, transplant program expansion, rare kidney disease funding. Major trends in the forecast period include increased focus on targeted immunosuppressive therapy, rising adoption of combination drug regimens, expansion of early diagnostic screening, growing use of renin-angiotensin system inhibitors, increased kidney transplant preparedness.

Global Focal Segmental Glomerulosclerosis Market Segmentation

1) By Disease Type: Primary Focal Segmental Glomerulosclerosis, Secondary Focal Segmental Glomerulosclerosis 2) By Treatment: Drug Therapy, Dialysis, Kidney Transplant, Other Treatments 3) By Drug Class: Immunosuppressants, Angiotensin Inhibitors, Corticosteroids 4) By Route Of Administration: Oral, Parenteral 5) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Primary Focal Segmental Glomerulosclerosis: Idiopathic Focal Segmental Glomerulosclerosis, Genetic Or Familial Focal Segmental Glomerulosclerosis, Collapsing Variant, Tip Lesion Variant, Cellular Variant, Perihilar Variant 2) By Secondary Focal Segmental Glomerulosclerosis: Virus-Associated Focal Segmental Glomerulosclerosis, Drug-Induced Focal Segmental Glomerulosclerosis, Adaptive Or Compensatory Focal Segmental Glomerulosclerosis, Other Secondary Causes

What Is The Driver Of The Focal Segmental Glomerulosclerosis Market?

The rising prevalence of kidney diseases is expected to propel the growth of the focal segmental glomerulosclerosis market going forward. Kidney diseases refer to conditions that impair the function and structure of the kidneys, affecting their ability to filter waste, balance fluids, and regulate essential body functions. The rising prevalence of kidney diseases is primarily due to diabetes, as high blood sugar levels over time damage the kidneys' filtering units, leading to diabetic nephropathy. Focal segmental glomerulosclerosis highlights the progressive scarring of kidney filters, serving as a critical indicator and target for understanding, diagnosing, and managing chronic kidney diseases. For instance, in August 2025, according to the American Kidney Fund, a U.S.-based nonprofit organization, 35.5 million Americans are living with chronic kidney disease (CKD), About 815,000 Americans are living with kidney failure, nearly 555,000 Americans are on dialysis. Therefore, the rising prevalence of kidney diseases is driving the focal segmental glomerulosclerosis industry.

Key Players In The Global Focal Segmental Glomerulosclerosis Market

Major companies operating in the focal segmental glomerulosclerosis market are Pfizer Inc., Merck And Co. Inc., Sanofi S.A., Eli Lilly and Company, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Mallinckrodt ARD LLC, Kyowa Kirin Co. Ltd., Aurinia Pharmaceuticals Inc., Travere Therapeutics Inc., Eledon Pharmaceuticals Inc., ZyVersa Therapeutics Inc., Complexa Inc., Certa Therapeutics, Delta 4 GmbH, Dimerix Limited, Goldfinch Bio Inc., Oraxion Therapeutics Inc., Variant Pharmaceuticals Inc.

Global Focal Segmental Glomerulosclerosis Market Trends and Insights

Major companies operating in the focal segmental glomerulosclerosis market are focusing on developing innovative therapies such as non-immunosuppressive oral medication to improve patient outcomes and reduce treatment side effects. Non-immunosuppressive oral medication is a drug taken by mouth that treats disease without weakening the immune system, helping manage focal segmental glomerulosclerosis by targeting kidney damage directly while avoiding immune-related side effects. For instance, in May 2025, Travere Therapeutics Inc., a US-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its supplemental New Drug Application (sNDA) for FILSPARI (sparsentan), granting traditional approval for the treatment of focal segmental glomerulosclerosis (FSGS). FILSPARI is a first-in-class therapy that works by simultaneously blocking both the endothelin type A receptor (ETAR) and the angiotensin II type 1 receptor (AT1R). This dual mechanism significantly reduces proteinuria in conditions such as FSGS and IgA nephropathy. Compared to existing treatments, FILSPARI offers improved kidney protection while maintaining a strong safety profile.

What Are Latest Mergers And Acquisitions In The Focal Segmental Glomerulosclerosis Market?

In August 2023, Novartis AG, a Switzerland-based pharmaceutical corporation, acquired Chinook Therapeutics Inc. for $3.5 billion. With this acquisition, Novartis aims to strengthen its position in rare kidney diseases by expanding its innovative pipeline with late-stage therapies for IgA nephropathy. Chinook Therapeutics Inc. is a US-based biotechnology company that is actively involved in the development of therapies for focal segmental glomerulosclerosis.

Regional Insights

North America was the largest region in the focal segmental glomerulosclerosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Focal Segmental Glomerulosclerosis Market?

The focal segmental glomerulosclerosis market consists of revenues earned by entities by providing services such as diagnostic testing, dialysis services, kidney transplant services, supportive care services, and medical imaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The focal segmental glomerulosclerosis market also includes sales of calcineurin inhibitors, mycophenolate mofetil, rituximab, sparsentan, and diuretics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Focal Segmental Glomerulosclerosis Market Report 2026?

The focal segmental glomerulosclerosis market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the focal segmental glomerulosclerosis industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.